Revised McDonald criteria allow earlier and more precise MS diagnosis Presented ByProf. Xavier Montalban, Vall d'Hebron University Hospital, Spain ConferenceECTRIMS 2024 TypeNews article 25 September 2024 11:03
Tolebrutinib slows disability in non-relapsing secondary progressive MS Presented ByProf. Robert Fox, Cleveland Clinic, OH, USA TrialPhase 3, HERCULES ConferenceECTRIMS 2024 TypeNews article 24 September 2024 10:45
B-cell-tailored dosing of ocrelizumab shows good results TrialPhase 4, BLOOMS ConferenceECTRIMS 2024 TypeNews article 23 September 2024 11:40
Revised McDonald criteria allow earlier and more precise MS diagnosis Presented ByProf. Xavier Montalban, Vall d'Hebron University Hospital, Spain ConferenceECTRIMS 2024 TypeNews article 25 September 2024 11:03
Blood markers predict MS progression Presented ByDr Ahmed Abdelhak, University of California San Francisco, USA ConferenceECTRIMS 2024 TypeNews article 25 September 2024 11:01
High depression genetic burden associated with MS disease activity Presented ByDr Kaarina Kowalec, University of Manitoba, Canada ConferenceECTRIMS 2024 TypeNews article 25 September 2024 11:00
More comorbidity is associated with worse clinical outcomes in MS Presented ByDr Amber Salter, University of Texas Southwestern, USA ConferenceECTRIMS 2024 TypeNews article 25 September 2024 10:58
First-line moderate-efficacy DMTs show similar efficacy Presented ByDr Clara López-Caneda, Hospital Alvaro Cunqueiro, Spain ConferenceECTRIMS 2024 TypeNews article 25 September 2024 10:57
Tolebrutinib slows disability in non-relapsing secondary progressive MS Presented ByProf. Robert Fox, Cleveland Clinic, OH, USA TrialPhase 3, HERCULES ConferenceECTRIMS 2024 TypeNews article 24 September 2024 10:45
Risk factors and importance of persistent PIRA ConferenceECTRIMS 2024 TypeNews article 24 September 2024 10:43
Frexalimab shows favourable safety and efficacy in OLE Presented ByProf. Gavin Giovannoni, Queen Mary University of London, UK TrialPhase 2 ConferenceECTRIMS 2024 TypeNews article 24 September 2024 10:40
Transfer of ocrelizumab into breastmilk is negligible Presented ByDr Riley Bove, University of California San Francisco, CA, USA TrialPhase 4, SOPRANINO ConferenceECTRIMS 2024 TypeNews article 24 September 2024 10:36
Ineffective response to EBV in MS not seen in similar diseases Presented ByDr Tilman Schneider-Hohendorf, University of Münster, Germany ConferenceECTRIMS 2024 TypeNews article 24 September 2024 10:33
Encouraging real-world results of AHSCT to treat aggressive MS Presented ByProf. Paolo Muraro, London Bridge Hospital, UK ConferenceECTRIMS 2024 TypeNews article 23 September 2024 11:42
B-cell-tailored dosing of ocrelizumab shows good results TrialPhase 4, BLOOMS ConferenceECTRIMS 2024 TypeNews article 23 September 2024 11:40
Tolebrutinib slows disability worsening in relapsing MS Presented ByDr Jiwon Oh, St. Michael's Hospital, Canada TrialPhase 3, GEMINI 1, GEMINI 2 ConferenceECTRIMS 2024 TypeNews article 23 September 2024 11:38
High-dose simvastatin does not slow disability progression in SPMS Presented ByProf. Jeremy Chataway, University College London, UK TrialPhase 3, MS-STAT2 ConferenceECTRIMS 2024 TypeNews article 23 September 2024 11:36
Gut microbiota modulates inflammation and cortical damage Presented ByDr Federico Montini, Brigham and Women's Hospital, Boston, MA, USA ConferenceECTRIMS 2024 TypeNews article 23 September 2024 11:35